alexa P53 Overexpression in Ductal Carcinoma in situ of the B
ISSN: 2157-7099

Journal of Cytology & Histology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

P53 Overexpression in Ductal Carcinoma in situ of the Breast

Kikuchi S1,3, Osako T1, Nishiyama Y1, Nakano M1, Tashima R1, Fujisue M1, Toyozumi Y2, Arima N2 and Nishimura R1*

1Department of Breast and Endocrine Surgery, Kumamoto City Hospital, Kumamoto 862-8505, Japan

2Departments of Breast Clinical Pathology, Kumamoto City Hospital, Kumamoto, Japan

3JSDF Kumamoto Hospital, Kumamoto 862-8505, Japan

*Corresponding Author:
Reiki Nishimura
Department of Breast and Endocrine Surgery
Kumamoto City Hospital, Kumamoto
1-1-60 Kotoh, Higashi-ku
Kumamoto City, Kumamoto 862-8505, Japan
Tel: +81-96-365-1711
Fax: +81-96-365-1712
Email: [email protected]

Received Date: July 10, 2014; Accepted Date: July 26, 2014,; Published Date: July 28, 2014

Citation: Kikuchi S, Osako T, Nishiyama Y, Nakano M, Tashima R, et al. (2014) P53 Overexpression in Ductal Carcinoma in situ of the Breast. J Cytol Histol 5:269. doi:10.4172/2157-7099.1000269

Copyright: © 2014 Kikuchi S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

Background: Ductal carcinoma in situ (DCIS) is the most common type of non-invasive breast cancer. DCIS is not life threatening but can increase the risk of invasive ductal carcinoma (IDC) development. However, the role of P53 expression in the progression to invasiveness in DCIS is unclear. In this retrospective study, the differences in biological markers, including protein 53 (P53) expression, between DCIS and IDC ≤5 mm in diameter (T1a) were evaluated.
Methods: Among 2,497 primary breast cancer patients, who underwent initial surgery between 2001 and 2010, 267 (10.4%) patients were diagnosed with DCIS and 86 (3.4%) patients were diagnosed with T1a. P53 expression was evaluated using immunohistochemical analysis, and the distribution (<10%, <50%, and ≥50%) and the association with other biological markers was investigated in DCIS and T1a.
Results: Overexpression (≥ 50%) of P53 was seen in 13% of patients with DCIS and in 24% of patients with T1a, constituting a significant difference (p=0.001). P53 overexpression was significantly associated with higher nuclear grade, lower rates of estrogen receptor (ER)/progesterone receptor (PgR) positivity, higher rates of epidermal growth factor receptor 2 (HER2) positivity, and higher values of nuclear protein Ki-67 in patients with DCIS. Recurrence rates did not differ significantly between DCIS and T1a. Logistic regression analysis of factors associated with invasiveness revealed that P53 overexpression was one of the significant factors, and ER negativity was found to be a significant independent factor in multivariate analysis.
Conclusion: P53 overexpression reflected the aggressiveness and correlated with the invasiveness in DCIS. These findings suggest that P53 may play an important role in invasion of DCIS in the breast.

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords